Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2019
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G Wierda, John C Byrd, Jeremy S Abramson, et al.Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.Blood|April 21, 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLWei Ding, Betsy R LaPlant, Timothy G Call, et al.Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.Pageof 9